Corbus Pharmaceuticals said on October 22, 2026, that CRB-913 data from its Phase 1b CANYON-1 obesity study are scheduled for a late-breaking poster presentation at ObesityWeek 2026. The November 15 presentation will cover efficacy, safety and tolerability, following topline results released in September.
Key Takeaways
- The CANYON-1 poster presentation is scheduled for November 15, 2026, from 2:30 to 3:30 p.m. ET.
- Corbus previously reported mean weight loss of 5% at 12 weeks in the 60 mg treatment group.
- The study remains early-stage; Corbus has said it expects to begin a Phase 2 monotherapy trial in the first half of 2027.
Table of Contents
- CRB-913 data presentation scheduled for November
- What the September trial results showed
- Development plans remain subject to further testing
- Conclusion
CRB-913 data presentation scheduled for November
Harold Bays, M.D., of the Louisville Metabolic and Atherosclerosis Research Center, is scheduled to present the poster at the Gaylord National Resort & Convention Center in National Harbor, Maryland. ObesityWeek runs from November 14 to 17, 2026.
The October announcement sets out the presentation arrangements rather than new numerical trial findings. The poster’s stated scope covers the efficacy, safety and tolerability of Corbus’s oral obesity drug candidate.
| Item | Details |
|---|---|
| Presentation format | Late-breaking scientific poster |
| Poster title | Efficacy, Safety, and Tolerability of CRB-913 in the Ph1b CANYON-1 Study |
| Session time | November 15, 2026, 2:30–3:30 p.m. ET |
| Room | Exhibit Hall BCD, Gaylord National Resort & Convention Center |
What the September trial results showed
In its September 14 CANYON-1 topline announcement, Corbus reported mean weight loss of 5% after 12 weeks at the 60 mg dose, compared with 0.0% for placebo. The company said weight loss had not plateaued by the end of treatment.
The double-blind, placebo-controlled trial enrolled 254 adults with obesity who did not have diabetes at 15 U.S. sites. Participants received one of three once-daily CRB-913 doses or placebo for 12 weeks, followed by four weeks of observation.
CRB-913 is a highly peripherally restricted CB1 inverse agonist being developed as an oral, non-incretin approach to obesity treatment. Corbus described the drug as generally well tolerated in the topline release. Its comparisons with other obesity drugs came from separate trials, not head-to-head testing, and therefore do not establish comparative safety or efficacy.
Development plans remain subject to further testing
In September, Corbus said it planned to engage with the U.S. Food and Drug Administration on clinical development and expected to initiate a Phase 2 monotherapy study in the first half of 2027. It was also evaluating the potential to combine CRB-913 with GLP-1 therapy.
Those are development plans, not completed milestones. Corbus cautioned that early-stage results may not predict outcomes in larger or later-stage trials, and that preliminary findings can change with additional patient data or analysis.
Conclusion
The next scheduled milestone is the November 15 poster presentation, where Corbus plans to detail the CANYON-1 findings. The presentation timing and subsequent clinical-development plans remain subject to change.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
